vs

Side-by-side financial comparison of LANDS' END, INC. (LE) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

LANDS' END, INC. is the larger business by last-quarter revenue ($317.5M vs $207.3M, roughly 1.5× Ultragenyx Pharmaceutical Inc.). LANDS' END, INC. runs the higher net margin — 1.6% vs -62.0%, a 63.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 0.1%). LANDS' END, INC. produced more free cash flow last quarter ($-22.4M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -0.9%).

Lands' End, Inc. is an American retailer of clothing, baggage, and furniture which began as a mail-order yachting supply company in 1963 in Chicago. The company is named after Land's End; after promotional materials were printed, the founder noticed the typographical error in the location of the apostrophe, but could not afford to reprint the material. The company operates 26 domestic stores as of February 2024. Lands' End is headquartered in Dodgeville, Wisconsin.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

LE vs RARE — Head-to-Head

Bigger by revenue
LE
LE
1.5× larger
LE
$317.5M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+25.8% gap
RARE
25.9%
0.1%
LE
Higher net margin
LE
LE
63.6% more per $
LE
1.6%
-62.0%
RARE
More free cash flow
LE
LE
$78.3M more FCF
LE
$-22.4M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-0.9%
LE

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
LE
LE
RARE
RARE
Revenue
$317.5M
$207.3M
Net Profit
$5.2M
$-128.6M
Gross Margin
51.8%
Operating Margin
5.3%
-54.7%
Net Margin
1.6%
-62.0%
Revenue YoY
0.1%
25.9%
Net Profit YoY
198.3%
3.5%
EPS (diluted)
$0.17
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LE
LE
RARE
RARE
Q4 25
$317.5M
$207.3M
Q3 25
$159.9M
Q2 25
$261.2M
$166.5M
Q1 25
$139.3M
Q4 24
$318.6M
$164.6M
Q3 24
$317.2M
$139.5M
Q2 24
$285.5M
$147.0M
Q1 24
$514.9M
$108.8M
Net Profit
LE
LE
RARE
RARE
Q4 25
$5.2M
$-128.6M
Q3 25
$-180.4M
Q2 25
$-8.3M
$-115.0M
Q1 25
$-151.1M
Q4 24
$-593.0K
$-133.2M
Q3 24
$-5.3M
$-133.5M
Q2 24
$-6.4M
$-131.6M
Q1 24
$-8.6M
$-170.7M
Gross Margin
LE
LE
RARE
RARE
Q4 25
51.8%
Q3 25
Q2 25
50.8%
Q1 25
Q4 24
50.6%
Q3 24
47.9%
Q2 24
48.7%
Q1 24
38.0%
Operating Margin
LE
LE
RARE
RARE
Q4 25
5.3%
-54.7%
Q3 25
-106.9%
Q2 25
-0.9%
-64.8%
Q1 25
-102.6%
Q4 24
2.9%
-74.3%
Q3 24
0.8%
-94.6%
Q2 24
0.8%
-79.1%
Q1 24
1.6%
-151.9%
Net Margin
LE
LE
RARE
RARE
Q4 25
1.6%
-62.0%
Q3 25
-112.8%
Q2 25
-3.2%
-69.0%
Q1 25
-108.5%
Q4 24
-0.2%
-80.9%
Q3 24
-1.7%
-95.7%
Q2 24
-2.3%
-89.5%
Q1 24
-1.7%
-156.8%
EPS (diluted)
LE
LE
RARE
RARE
Q4 25
$0.17
$-1.28
Q3 25
$-1.81
Q2 25
$-0.27
$-1.17
Q1 25
$-1.57
Q4 24
$-0.02
$-1.34
Q3 24
$-0.17
$-1.40
Q2 24
$-0.20
$-1.52
Q1 24
$-0.27
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LE
LE
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$36.3M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$231.0M
$-80.0M
Total Assets
$852.7M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LE
LE
RARE
RARE
Q4 25
$36.3M
$421.0M
Q3 25
$202.5M
Q2 25
$18.1M
$176.3M
Q1 25
$127.1M
Q4 24
$30.4M
$174.0M
Q3 24
$25.6M
$150.6M
Q2 24
$27.4M
$480.7M
Q1 24
$25.3M
$112.3M
Stockholders' Equity
LE
LE
RARE
RARE
Q4 25
$231.0M
$-80.0M
Q3 25
$9.2M
Q2 25
$230.1M
$151.3M
Q1 25
$144.2M
Q4 24
$223.6M
$255.0M
Q3 24
$226.5M
$346.8M
Q2 24
$234.6M
$432.4M
Q1 24
$241.6M
$140.3M
Total Assets
LE
LE
RARE
RARE
Q4 25
$852.7M
$1.5B
Q3 25
$1.2B
Q2 25
$760.5M
$1.3B
Q1 25
$1.3B
Q4 24
$843.6M
$1.5B
Q3 24
$802.5M
$1.5B
Q2 24
$800.1M
$1.6B
Q1 24
$811.5M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LE
LE
RARE
RARE
Operating Cash FlowLast quarter
$-15.7M
$-99.8M
Free Cash FlowOCF − Capex
$-22.4M
$-100.8M
FCF MarginFCF / Revenue
-7.1%
-48.6%
Capex IntensityCapex / Revenue
2.1%
0.5%
Cash ConversionOCF / Net Profit
-3.03×
TTM Free Cash FlowTrailing 4 quarters
$-55.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LE
LE
RARE
RARE
Q4 25
$-15.7M
$-99.8M
Q3 25
$-91.4M
Q2 25
$-22.5M
$-108.3M
Q1 25
$-166.5M
Q4 24
$-17.1M
$-79.3M
Q3 24
$30.7M
$-67.0M
Q2 24
$-25.8M
$-77.0M
Q1 24
$93.9M
$-190.7M
Free Cash Flow
LE
LE
RARE
RARE
Q4 25
$-22.4M
$-100.8M
Q3 25
$-92.7M
Q2 25
$-30.7M
$-110.7M
Q1 25
$-167.8M
Q4 24
$-27.8M
$-79.5M
Q3 24
$26.0M
$-68.6M
Q2 24
$-32.6M
$-79.0M
Q1 24
$87.5M
$-193.9M
FCF Margin
LE
LE
RARE
RARE
Q4 25
-7.1%
-48.6%
Q3 25
-58.0%
Q2 25
-11.8%
-66.5%
Q1 25
-120.5%
Q4 24
-8.7%
-48.3%
Q3 24
8.2%
-49.2%
Q2 24
-11.4%
-53.7%
Q1 24
17.0%
-178.2%
Capex Intensity
LE
LE
RARE
RARE
Q4 25
2.1%
0.5%
Q3 25
0.8%
Q2 25
3.2%
1.5%
Q1 25
1.0%
Q4 24
3.3%
0.1%
Q3 24
1.5%
1.2%
Q2 24
2.4%
1.4%
Q1 24
1.2%
3.0%
Cash Conversion
LE
LE
RARE
RARE
Q4 25
-3.03×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LE
LE

U Se Commerce$179.8M57%
Business Outfitters Revenue$78.8M25%
Licensing And Retail$20.2M6%
Other$19.8M6%
Third Party$18.9M6%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons